Coalition for Epidemic Preparedness Innovations

Scientists are developing four Ebola vaccines to address the Bundibugyo strain outbreak in eastern DR Congo, with two candidates potentially entering clinical trials by summer. The outbreak, which has reported over 500 cases, faces challenges including delayed detection and reduced health resources due to aid cuts. The Africa CDC has urged strengthened border screening measures to prevent cross-border transmission.

A global coalition is fast-tracking three vaccines targeting the Bundibugyo ebolavirus, with $62 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The current outbreak in the Democratic Republic of Congo lacks a licensed vaccine, as Merck’s Ervebo only targets the Zaire ebolavirus.

CEPI has committed $50 million to Moderna for preclinical development and Phase 1 testing of an mRNA-based vaccine against Bundibugyo ebolavirus (BDBV). The funding aims to accelerate efforts to address an outbreak in the Democratic Republic of the Congo, leveraging Moderna's mRNA platform used during the COVID-19 pandemic.

Congo reports 282 confirmed Ebola cases in an outbreak linked to the Bundibugyo virus, with 42 deaths in Congo and one in Uganda. Recovery stories of medical workers highlight progress despite challenges in containment, while a $62 million commitment accelerates vaccine development.

Congo's Ebola outbreak has confirmed 282 cases, primarily in Ituri province, with survivors sharing stories of recovery. The Bundibugyo virus species has no approved treatment or vaccine, and the World Health Organization highlights challenges in containment. Uganda has closed its border with Congo to limit spread.

Congo's Ebola outbreak has confirmed 282 cases, primarily in Ituri province, with survivors sharing recovery experiences. The Bundibugyo virus, lacking approved treatments or vaccines, has spread across 22 health zones. The Coalition for Epidemic Preparedness Innovations pledged $62 million for experimental vaccines, while WHO honored health workers as survivors.

The Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to develop and test Moderna's vaccine against the Bundibugyo strain of Ebola. The funding may also support manufacturing and later-stage trials if early data are positive.

Congo reports 282 confirmed Ebola cases in its eastern provinces, with the outbreak primarily affecting Ituri province. Survivors describe their recovery experiences, while international efforts focus on developing vaccines and improving containment measures. Neighboring Uganda has closed its border to limit spread.